Literature DB >> 24633675

Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine.

Nan Wang1, Guang-Fen Zhang, Xiao-Yu Liu, He-Liang Sun, Xing-Ming Wang, Li-Li Qiu, Chun Yang, Jian-Jun Yang.   

Abstract

Increasing evidence underscores the strong, rapid, and sustained antidepressant properties of ketamine with a good tolerability profile in patients with depression; however, the underlying mechanisms are not fully elucidated. Neuregulin 1 (NRG1) is a bipolar disorder susceptibility gene and a biomarker of major depressive disorder, which regulates pyramidal neuron activity via ErbB4 in parvalbumin interneurons. Moreover, NRG1-ErbB4 signaling is reported to play a key role in the modulation of synaptic plasticity through regulating the neurotransmission. We therefore hypothesized that hypofunction of NRG1-ErbB4 signaling in parvalbumin interneurons is involved in the process of ketamine exerting rapid antidepressant actions in rats subjected to the forced swimming test (FST). The results showed that ketamine reduced the immobility time and latency to feed of rats receiving the FST, downregulated the levels of NRG1, phosphorylated ErbB4 (p-ErbB4), parvalbumin, 67-kDA isoform of glutamic acid decarboxylase (GAD67), gamma-aminobutyric acid (GABA), and upregulated the levels of glutamate in the rat prefrontal cortex and hippocampus. Pretreatment with NRG1 abolished both ketamine's antidepressant effects and ketamine-induced reduction in p-ErbB4, parvalbumin, GAD67, and GABA levels and increase in glutamate levels. These results suggest that the downregulation of NRG1-ErbB4 signaling in parvalbumin interneurons in the rat brain may be a mechanism underlying ketamine's antidepressant properties.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633675     DOI: 10.1007/s12031-014-0277-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  32 in total

1.  Different patterns of abnormal gamma oscillatory activity in unipolar and bipolar disorder patients during an implicit emotion task.

Authors:  Tai-Ying Liu; Jen-Chuen Hsieh; Yong-Sheng Chen; Pei-Chi Tu; Tung-Ping Su; Li-Fen Chen
Journal:  Neuropsychologia       Date:  2012-03-08       Impact factor: 3.139

Review 2.  Differentiating antidepressants of the future: efficacy and safety.

Authors:  Sharon Rosenzweig-Lipson; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Somana J Rajarao; Jessica E Malberg; Zia Rahman; Robert H Ring; Lee E Schechter
Journal:  Pharmacol Ther       Date:  2006-09-27       Impact factor: 12.310

3.  Neuregulin 1 regulates excitability of fast-spiking neurons through Kv1.1 and acts in epilepsy.

Authors:  Ke-Xin Li; Ying-Mei Lu; Zheng-Hao Xu; Jing Zhang; Jun-Ming Zhu; Jian-Ming Zhang; Shu-Xia Cao; Xiao-Juan Chen; Zhong Chen; Jian-Hong Luo; Shumin Duan; Xiao-Ming Li
Journal:  Nat Neurosci       Date:  2011-12-11       Impact factor: 24.884

4.  Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.

Authors:  E Beurel; L Song; R S Jope
Journal:  Mol Psychiatry       Date:  2011-04-19       Impact factor: 15.992

5.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

Review 6.  Human gamma-frequency oscillations associated with attention and memory.

Authors:  Ole Jensen; Jochen Kaiser; Jean-Philippe Lachaux
Journal:  Trends Neurosci       Date:  2007-05-17       Impact factor: 13.837

7.  Driving fast-spiking cells induces gamma rhythm and controls sensory responses.

Authors:  Jessica A Cardin; Marie Carlén; Konstantinos Meletis; Ulf Knoblich; Feng Zhang; Karl Deisseroth; Li-Huei Tsai; Christopher I Moore
Journal:  Nature       Date:  2009-04-26       Impact factor: 49.962

8.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

9.  VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants.

Authors:  Jennifer L Warner-Schmidt; Ronald S Duman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

10.  Excitation Control: Balancing PSD-95 Function at the Synapse.

Authors:  Dove Keith; Alaa El-Husseini
Journal:  Front Mol Neurosci       Date:  2008-03-28       Impact factor: 5.639

View more
  19 in total

1.  Journal of molecular neuroscience: impacting our brains.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2014-11       Impact factor: 3.444

2.  Chronic Stress Increases Prefrontal Inhibition: A Mechanism for Stress-Induced Prefrontal Dysfunction.

Authors:  Jessica M McKlveen; Rachel L Morano; Maureen Fitzgerald; Sandra Zoubovsky; Sarah N Cassella; Jessie R Scheimann; Sriparna Ghosal; Parinaz Mahbod; Benjamin A Packard; Brent Myers; Mark L Baccei; James P Herman
Journal:  Biol Psychiatry       Date:  2016-03-28       Impact factor: 13.382

3.  The laterodorsal tegmentum-ventral tegmental area circuit controls depression-like behaviors by activating ErbB4 in DA neurons.

Authors:  Hongsheng Wang; Wanpeng Cui; Wenbing Chen; Fang Liu; Zhaoqi Dong; Guanglin Xing; Bin Luo; Nannan Gao; Wen-Jun Zou; Kai Zhao; Hongsheng Zhang; Xiao Ren; Zheng Yu; Heath L Robinson; Zhipeng Liu; Wen-Cheng Xiong; Lin Mei
Journal:  Mol Psychiatry       Date:  2021-05-14       Impact factor: 15.992

Review 4.  Mechanisms of ketamine and its metabolites as antidepressants.

Authors:  Evan M Hess; Lace M Riggs; Michael Michaelides; Todd D Gould
Journal:  Biochem Pharmacol       Date:  2021-12-27       Impact factor: 5.858

Review 5.  Parvalbumin interneuron alterations in stress-related mood disorders: A systematic review.

Authors:  George Perlman; Arnaud Tanti; Naguib Mechawar
Journal:  Neurobiol Stress       Date:  2021-08-12

6.  Quantification of Tyrosine Hydroxylase and ErbB4 in the Locus Coeruleus of Mood Disorder Patients Using a Multispectral Method to Prevent Interference with Immunocytochemical Signals by Neuromelanin.

Authors:  Lei Guo; Jochem Stormmesand; Zheng Fang; Qingbin Zhu; Rawien Balesar; Joop van Heerikhuize; Arja Sluiter; Dick Swaab; Ai-Min Bao
Journal:  Neurosci Bull       Date:  2019-01-31       Impact factor: 5.203

7.  Prenatal dexamethasone exposure induces anxiety- and depressive-like behavior of male offspring rats through intrauterine programming of the activation of NRG1-ErbB4 signaling in hippocampal PV interneurons.

Authors:  Shuai Zhang; Shuwei Hu; Wanting Dong; Songqiang Huang; Zhexiao Jiao; Zewen Hu; Shiyun Dai; Yiwen Yi; Xiaohan Gong; Ke Li; Hui Wang; Dan Xu
Journal:  Cell Biol Toxicol       Date:  2021-06-29       Impact factor: 6.691

8.  Downregulation of neuregulin 1-ErbB4 signaling and antidepressant properties of ketamine: ErbB4 expressing pyramidal neurons may play a role.

Authors:  Hans-Gert Bernstein; Gerburg Keilhoff; Johann Steiner; Gregor Laube; Bernhard Bogerts
Journal:  J Mol Neurosci       Date:  2014-05-30       Impact factor: 3.444

9.  MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine.

Authors:  Xiaolin Yang; Qinyan Yang; Xiaobin Wang; Chunqiong Luo; Yunqiang Wan; Jiali Li; Kezhi Liu; Min Zhou; Chunxiang Zhang
Journal:  Neuromolecular Med       Date:  2014-05-18       Impact factor: 3.843

10.  Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression.

Authors:  Lucia Carboni; Luca Marchetti; Mario Lauria; Peter Gass; Barbara Vollmayr; Amanda Redfern; Lesley Jones; Maria Razzoli; Karim Malki; Veronica Begni; Marco A Riva; Enrico Domenici; Laura Caberlotto; Aleksander A Mathé
Journal:  Neuropsychopharmacology       Date:  2018-06-12       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.